Criteria for the diagnosis and treatment of gestational diabetes mellitus—time for a change

2011 ◽  
Vol 7 (4) ◽  
pp. 185-185
Author(s):  
Carol Wilson
Keyword(s):  
Diabetes Mellitus ◽  
Gestational Diabetes ◽  
Gestational Diabetes Mellitus ◽  
Diagnosis And Treatment

scholarly journals Gestational Diabetes Mellitus: Developments in Diagnosis and Treatment

2009 ◽  
Vol 5 (3) ◽  
pp. 263-268
Author(s):  
Robert Fraser
Keyword(s):  
Diabetes Mellitus ◽  
Glycemic Control ◽  
Gestational Diabetes ◽  
Gestational Diabetes Mellitus ◽  
Pregnant Women ◽  
Diagnosis And Treatment ◽  
Screening Programs ◽  
First Choice ◽  
Carbohydrate Intolerance

After many years of uncertainty regarding the true pathological nature of mild gestational diabetes and the possible benefits of treatment, the situation appears to have been resolved by the publication of the Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS). It is now appropriate for obstetric units to review their treatment and screening programs for gestational diabetes mellitus. Furthermore, with the publication of the Metformin in Gestational Diabetes (MiG) trial, consideration should be given as to whether metformin should be the first choice when diet fails to maintain glycemic control.

Gestational diabetes mellitus: Prevention, diagnosis and treatment. A fresh look to a busy corner

2020 ◽  
Vol 13 (4) ◽  
pp. 529-541 ◽  
Author(s):  
G. Zito ◽  
L. Della Corte ◽  
P. Giampaolino ◽  
M. Terzic ◽  
S. Terzic ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Gestational Diabetes ◽  
Gestational Diabetes Mellitus ◽  
Treatment Strategies ◽  
Diagnosis And Treatment ◽  
Cochrane Library ◽  
Level Control ◽  
Pregnancy Risk ◽  
Family History Of Diabetes ◽  
Nutritional Interventions

BACKGROUND: Gestational diabetes mellitus (GDM) is a common pregnancy complication characterized by hyperglycaemia with onset or first recognition during pregnancy. Risk factors include family history of diabetes, previous GDM, genetic predisposition for GDM/type 2 diabetes, insulin resistance conditions such as overweight, obesity and ethnicity. Women with GDM are at high risk for fetal macrosomia, small for gestational age, neonatal hypoglycaemia, operative delivery and caesarean delivery. The aim of this narrative review is to summarize the most recent findings of diagnosis and treatment of GDM in order to underline the importance to promote adequate prevention of this disease, especially through lifestyle interventions such as diet and physical activity. METHODS: The research was conducted using the following electronic databases, MEDLINE, EMBASE, Web of Science, Scopus, ClinicalTrial.gov, OVID and Cochrane Library, including all published randomized and non-randomized studies as well as narrative and systematic reviews. RESULTS: The lack of universally accepted criteria makes the definition of diagnosis and prognosis of this condition difficult. Early diagnosis and glucose blood level control may improve maternal and fetal short and long-term outcomes. Treatment strategies include nutritional interventions and exercise. Medical treatment can be necessary if these strategies are not effective. Moreover, novel non-pharmacologic agents such as myo-inositol seem to be effective and safe both in the prevention and the treatment of GDM. CONCLUSIONS: It is important to promote adequate prevention of GDM. Further studies are needed in order to better define the most appropriate strategies for the clinical management of women affected by GDM.

scholarly journals Myoinositol in the Prevention of Gestational Diabetes Mellitus: Is It Sensible?

2019 ◽  
Vol 2019 ◽  
pp. 1-5 ◽  
Author(s):  
Angelika Sobota-Grzeszyk ◽  
Mariusz Kuźmicki ◽  
Jacek Szamatowicz
Keyword(s):  
Diabetes Mellitus ◽  
Insulin Sensitivity ◽  
Side Effects ◽  
Gestational Diabetes ◽  
Gestational Diabetes Mellitus ◽  
Pregnant Women ◽  
Adverse Outcomes ◽  
Diagnosis And Treatment

Gestational diabetes mellitus (GDM) is a complication that increasingly affects pregnant women. Due to the risk of adverse outcomes in the mother as well as in the fetus which is caused by GDM, appropriate diagnosis and treatment is very essential. Nevertheless, it is important to find new, effective ways of prevention of GDM to avoid side effects. A promising example of such an action may be supplementation of myoinositol. As shown in studies, myoinositol may reduce the risk of developing gestational diabetes mellitus by improving insulin sensitivity.

scholarly journals Changes of Plasma Phospholipid Fatty Acids Profiles in Pregnancy in Relation to the Diagnosis and Treatment of Gestational Diabetes Mellitus

2021 ◽  
Author(s):  
Lingjun Li ◽  
Yeyi Zhu ◽  
Jing Wu ◽  
Stefanie N Hinkle ◽  
Deirdre K Tobias ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Fatty Acids ◽  
Gestational Diabetes ◽  
Gestational Diabetes Mellitus ◽  
Vaccenic Acid ◽  
Plasma Phospholipid ◽  
Phospholipid Fatty Acids ◽  
Diagnosis And Treatment ◽  
Alpha Linolenic Acid ◽  
Before And After

Abstract Background Plasma phospholipid fatty acids (FAs) in early and mid-pregnancy have been prospectively related to gestational diabetes mellitus (GDM) risk. Yet, changes of FAs following GDM diagnosis and treatment and their implications for glucose metabolism and control remain understudied. Methods From the Eunice Kennedy Shriver National Institute Child Health and Human Development Fetal Growth Studies–Singleton Cohort of 2802 pregnant women, we ascertained 85 GDM cases using the Carpenter and Coustan criteria and 85 non-GDM controls after exclusion. Using plasma collected before (23–31 weeks) and after GDM diagnosis (33–39 weeks), we quantified 25 saturated, poly- and monounsaturated FAs levels. We estimated the fold change of FAs before and after GDM diagnosis, using multiple linear mixed models adjusting for confounders. Results Eight FAs showed significant fold changes from the baseline values (23–31 weeks) among GDM cases as compared to women without GDM. Five FAs showed reduced fold changes [myristic acid (14:0): β: −0.22 (95% CI: −0.30, −0.14), palmitic acid (16:0): β: −0.02 (95% CI: −0.04, −0.01), cis-palmitoleic acid (16:1n7): β: −0.15 (95% CI: −0.24, −0.05), alpha-linolenic acid (18:3n3): β: −0.19 (95% CI: −0.31, −0.07], and dihomo-gamma-linoleic acid (20:3n6): β:−0.16; 95% CI: −0.21, −0.11)], whereas 3 showed increases [heptadecanoic acid (17:0): β: 0.17 (95% CI: 0.11, 0.22), cis-vaccenic acid (18:1n7): β: 0.06 (95% CI: 0.03, 0.10), and arachidonic acid (20:4n6): β: 0.10 (95% CI: 0.06, 0.13)]. Conclusions Our study identified 8 FAs with unique patterns of change before and after GDM diagnosis that differed significantly between women with and without GDM. Our findings may shed light on the role of FA metabolism in the pathophysiology and disease management and progression of GDM. Clinical Trial Registry NCT00912132

scholarly journals The results of the use of new criteria for the diagnosis and treatment of gestational diabetes mellitus

2015 ◽  
Vol 64 (4) ◽  
pp. 21-25
Author(s):  
Natal’ya Viktorovna Borovik ◽  
Alena Viktorovna Tiselko ◽  
Ol’ga Nikolaevna Arzhanova ◽  
Roman Viktorovich Kapustin ◽  
Vladimir Vsevolodovich Potin ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Gestational Diabetes ◽  
Gestational Diabetes Mellitus ◽  
Pregnancy Outcomes ◽  
Efficient Algorithm ◽  
High Rate ◽  
Diagnosis And Treatment ◽  
Control Group ◽  
Perinatal Complications ◽  
New Criteria

Taking into consideration the high rate of perinatal complications in women with gestational diabetes, we need to develop the efficient algorithm for the diagnosis and treatment of this disease. We have analyzed the specificity of the course and pregnancy outcomes for 500 women who used the new clinical guidelines of diagnosis and treatment of gestational diabetes mellitus (GDM). The control group includes 100 women with GDM (criteria of V. G. Baranov, 1977). Analysis of the results is necessary to optimize the tactics of the treatment for this group of patients.

Relationship between environmental temperature and the diagnosis and treatment of gestational diabetes mellitus: An observational retrospective study

2020 ◽  
Vol 744 ◽  
pp. 140994 ◽  
Author(s):  
Maria Molina-Vega ◽  
Carolina Gutiérrez-Repiso ◽  
Araceli Muñoz-Garach ◽  
Fuensanta Lima-Rubio ◽  
Sonsoles Morcillo ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Retrospective Study ◽  
Gestational Diabetes ◽  
Gestational Diabetes Mellitus ◽  
Environmental Temperature ◽  
Diagnosis And Treatment

scholarly journals MiRNAs in Gestational Diabetes Mellitus: Potential Mechanisms and Clinical Applications

2021 ◽  
Vol 2021 ◽  
pp. 1-14
Author(s):  
Zhao-Nan Liu ◽  
Ying Jiang ◽  
Xuan-Qi Liu ◽  
Meng-Meng Yang ◽  
Cheng Chen ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Gestational Diabetes ◽  
Gestational Diabetes Mellitus ◽  
Potential Function ◽  
Therapeutic Approach ◽  
Diagnosis And Treatment ◽  
Pathophysiological Mechanism ◽  
Small Noncoding Rnas ◽  
Offspring Health ◽  
Postpartum Outcomes

Gestational diabetes mellitus (GDM) is a common pregnancy complication which is normally diagnosed in the second trimester of gestation. With an increasing incidence, GDM poses a significant threat to maternal and offspring health. Therefore, we need a deeper understanding of GDM pathophysiology and novel investigation on the diagnosis and treatment for GDM. MicroRNAs (miRNAs), a class of endogenic small noncoding RNAs with a length of approximately 19-24 nucleotides, have been reported to exert their function in gene expression by binding to proteins or being enclosed in membranous vesicles, such as exosomes. Studies have investigated the roles of miRNAs in the pathophysiological mechanism of GDM and their potential as noninvasive biological candidates for the management of GDM, including diagnosis and treatment. This review is aimed at summarizing the pathophysiological significance of miRNAs in GDM development and their potential function in GDM clinical diagnosis and therapeutic approach. In this review, we summarized an integrated expressional profile and the pathophysiological significance of placental exosomes and associated miRNAs, as well as other plasma miRNAs such as exo-AT. Furthermore, we also discussed the practical application of exosomes in GDM postpartum outcomes and the potential function of several miRNAs as therapeutic target in the GDM pathological pathway, thus providing a novel clinical insight of these biological signatures into GDM therapeutic approach.

Sign in / Sign up

Export Citation Format

Share Document